Weekly Cumulative Estimated Number of RSV Vaccinations Administered in Pharmacies and Physician Medical Offices, Adults 60 Years and Older, United States

• Estimated Number of RSV vaccinations among adults 60 years and older is assessed through IQVIA (https://www.iqvia.com/) as a source of information on vaccinations administered in retail pharmacies (include chain, mass merchandise, food stores, and independent pharmacies) and physician medical offices.

• Starting in September 2023, the CDC recommended the RSV vaccine for adults 60 years and older.

Monthly Cumulative Number and Percent of Children <20 Months Who Received Nirsevimab by Age Group and Jurisdiction

• Estimated nirsevimab coverage for children 0-19 months is assessed through U.S. jurisdictions’ Immunization Information Systems (IIS) data, submitted from jurisdictions to CDC monthly in aggregate by age group.

• Starting in July 2023, the CDC recommended the RSV vaccine to protect against serious illness from RSV. (https://www.cdc.gov/respiratory-viruses/whats-new/rsv-update-2023-09-22.html)
 

Monthly Nirsevimab Receipt and Intent Among Females Aged 18-49 Years Who Have a Baby <8 Months, Are Currently Pregnant, or Are Trying to Get Pregnant.

• Using data from the National Immunization Survey-Adult COVID Module (NIS-ACM), monthly estimates of receipt and intent for baby’s receipt of nirsevimab reported by females aged 18-49 years with infants under the age of 8 months, females aged 18-49 years who are currently pregnant, and females aged 18-49 years who are currently trying to get pregnant.

• The NIS-ACM is an ongoing random-digit-dial cellular telephone survey of households with adults 18 years and older.

Monthly Cumulative Number and Percent of Adults 60 Years and Older Who Received at least one RSV Vaccination Doses by Jurisdiction

• Estimated Respiratory Syncytial Virus (RSV) vaccination coverage for adults is assessed through U.S. jurisdictions’ Immunization Information Systems (IIS) data, submitted from jurisdictions to CDC monthly in aggregate by age group.

• Starting in July 2023, the CDC recommended the RSV vaccine to protect against serious illness from RSV. (https://www.cdc.gov/respiratory-viruses/whats-new/rsv-update-2023-09-22.html)
 

• Weekly Cumulative RSV Vaccination Coverage and Intent Among Adults 75 Years and Older and 60─74 Years with High Risk Conditions Ever Vaccinated with RSV Vaccine by Demographic Characteristics and Jurisdiction
• Weekly estimates of RSV vaccination coverage and intent among adults 75 years and older and 60─74 years with high risk conditions are calculated using data from the National Immunization Survey–Adult COVID Module (NIS–ACM)(https://www.cdc.gov/nis/about/).
• In June 2023, the Advisory Committee on Immunization Practices (ACIP) voted to recommend that adults aged ≥60 years may receive a single dose of an RSV vaccine, using shared clinical decision-making. In June 2024, the ACIP voted to recommend a single dose of RSV vaccine for all adults 75 years and older and adults 60–74 years who are at increased risk for severe RSV disease. The data below captures ever receiving a dose of an RSV vaccine by adults 60 years and older.

• Weekly RSV Vaccination Coverage, Pregnant Persons 18-49 Years Old by Race and Ethnicity

• Weekly RSV vaccination coverage estimates for pregnant persons ages 18–49 years are based on electronic health record (EHR) data from the Vaccine Safety Datalink (VSD)(https://www.cdc.gov/vaccine-safety-systems/vsd/), a collaboration between CDC’s Immunization Safety Office and multiple integrated health care organizations.

Monthly Nirsevimab Monthly Nirsevimab Receipt and Intent Reported by Females Aged 18-49 Years With infants <8 Months During the RSV Season (born since April 1, 2024)

Monthly estimates of receipt and intent for nirsevimab reported by adult females aged 18–49 years with infants under the age of 8 months during the RSV season (born since April 1, 2024) using data from the National Immunization Survey–Adult COVID Module (NIS–ACM). (https://www.cdc.gov/nis/about/). The NIS–ACM is an ongoing random-digit-dial cellular telephone survey of households with adults 18 years and older. All estimates are based upon parent-reported receipt of nirsevimab.

• Weekly Cumulative RSV Vaccination Coverage and Intent Among Adults 75 Years and Older and 60─74 Years with High Risk Conditions Ever Vaccinated with RSV Vaccine by Demographic Characteristics and Jurisdiction
• Weekly estimates of RSV vaccination coverage and intent among adults 75 years and older and 60─74 years with high risk conditions are calculated using data from the National Immunization Survey–Adult COVID Module (NIS–ACM) (https://www.cdc.gov/nis/about/)
• In June 2023, the Advisory Committee on Immunization Practices (ACIP) voted to recommend that adults aged ≥60 years may receive a single dose of an RSV vaccine, using shared clinical decision-making. In June 2024, the ACIP voted to recommend a single dose of RSV vaccine for all adults 75 years and older and adults 60–74 years who are at increased risk for severe RSV disease. The data below captures ever receiving a dose of an RSV vaccine by adults 60 years and older. 

• Weekly Cumulative RSV Vaccination Coverage and Intent Among Adults 75 Years and Older and 60─74 Years with High Risk Conditions Ever Vaccinated with RSV Vaccine by Demographic Characteristics and Jurisdiction

• Weekly estimates of RSV vaccination coverage and intent among adults 75 years and older and 60─74 years with high risk conditions are calculated using data from the National Immunization Survey–Adult COVID Module (NIS–ACM) (https://www.cdc.gov/nis/about/index.html).

• In June 2023, the Advisory Committee on Immunization Practices (ACIP) voted to recommend that adults aged ≥60 years may receive a single dose of an RSV vaccine, using shared clinical decision-making. In June 2024, the ACIP voted to recommend a single dose of RSV vaccine for all adults 75 years and older and adults 60–74 years who are at increased risk for severe RSV disease. The data below captures ever receiving a dose of an RSV vaccine by adults 60 years and older.